^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Waldenstrom Macroglobulinemia
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Ninlaro (ixazomib) (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN Panel has included ixazomib/rituximab/dexamethasone as a treatment option under other recommended regimens for primary therapy…
    Secondary therapy:
    dexamethasone